A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer
- Determine the efficacy of arsenic trioxide in patients with unresectable metastatic
- Determine the safety and tolerability of this drug in these patients.
OUTLINE: Patients receive a loading dose of arsenic trioxide IV over 1-2 hours once daily on
days 1-5* in week 1 and then twice weekly in weeks 2-8. Courses repeat every 8 weeks in the
absence of disease progression or unacceptable toxicity.
NOTE: *The 5-day loading dose is only administered during course 1.
After completion of study treatment, patients are followed at 30 days and then periodically
for up to 2 years.
PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
T. Clark Gamblin, MD
UPMC Cancer Center at UPMC Presbyterian
United States: Federal Government
|UPMC Cancer Centers||Pittsburgh, Pennsylvania 15232|